MOTS-c
Regulatory status · United States · as of October 2026
Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. On July 23, 2026, the advisory committee voted 7–5 (two abstentions) to recommend it for the 503A Bulks List, against the advice of FDA's scientists. FDA has not decided; it cannot yet be compounded under section 503A.
Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026
Researched forInsulin sensitivity, exercise capacity, metabolic regulation, aging biology.
Full profile: MOTS-c →